Education
About Us
Working with TipRanks
Follow Us
Zai Lab Ltd (ZLAB)
:ZLAB
ZLAB Stock Chart & Stats
$26.34
-$1.34(-5.19%)
At close: 4:00 PM EST
$26.34
-$1.34(-5.19%)
Day’s Range― - ―
52-Week Range$23.82 - $44.34
Previous CloseN/A
Volume273.50K
Average Volume (3M)608.67K
Market Cap
$3.10B
Enterprise Value$3.18B
Total Cash (Recent Filing)$732.16M
Total Debt (Recent Filing)$191.40M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Nov 11, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding111,762,800
10 Day Avg. Volume757,102
30 Day Avg. Volume608,669
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)3.08
Price to Sales (P/S)6.50
P/FCF Ratio-9.38
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue7.43
Enterprise Value/Gross Profit11.89
Enterprise Value/Ebitda-14.98
Forecast
1Y Price Target
$55.63Price Target Upside111.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Clinical Trials And EfficacyZoci’s strong CNS penetration/activity, particularly in patients with untreated brain mets, is noteworthy and appears to be a population excluded from competitor trials.
Pipeline Strength And ManagementThe company's broad pipeline of commercial and development-stage assets and a management team with extensive experience in the biopharma landscape contribute to a positive view on ZLAB.
Revenue And Profitability GuidanceManagement reiterated their 2025 full year revenue guidance and their goal of achieving profitability in 4Q25.
Bears Say
Competitive PressureThe sales decrease of ZEJULA is mainly due to intense competition in the PARP inhibitor market.
Revenue Performance2Q25 earnings release reported below-consensus total revenues, though full-year revenue guidance was reaffirmed.
Stock Price And RatingsMuted revenue growth in 2Q25 with lower price objective to US$39.0 and a neutral rating reiteration.
Zai Lab News
ZLAB FAQ
What was Zai Lab Ltd’s price range in the past 12 months?
Zai Lab Ltd lowest stock price was $23.82 and its highest was $44.34 in the past 12 months.
What is Zai Lab Ltd’s market cap?
Zai Lab Ltd’s market cap is $3.10B.
When is Zai Lab Ltd’s upcoming earnings report date?
Zai Lab Ltd’s upcoming earnings report date is Nov 11, 2025 which is in 13 days.
How were Zai Lab Ltd’s earnings last quarter?
Zai Lab Ltd released its earnings results on Aug 07, 2025. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.358 by -$0.012.
Is Zai Lab Ltd overvalued?
According to Wall Street analysts Zai Lab Ltd’s price is currently Undervalued.
Does Zai Lab Ltd pay dividends?
Zai Lab Ltd does not currently pay dividends.
What is Zai Lab Ltd’s EPS estimate?
Zai Lab Ltd’s EPS estimate is -0.29.
How many shares outstanding does Zai Lab Ltd have?
Zai Lab Ltd has 111,762,800 shares outstanding.
What happened to Zai Lab Ltd’s price movement after its last earnings report?
Zai Lab Ltd reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.358. Following the earnings report the stock price went down -11.983%.
Which hedge fund is a major shareholder of Zai Lab Ltd?
Currently, no hedge funds are holding shares in ZLAB
Zai Lab Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.63 (111.20% Upside)
$55.63 (111.20% Upside)
Blogger Sentiment
Bullish
ZLAB Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $289.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.62%
12-Months-Change
Fundamentals
Return on Equity
-28.39%
Trailing 12-Months
Asset Growth
17.90%
Trailing 12-Months
Company Description
Zai Lab Ltd
Zai Lab Limited is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, focused on discovering, developing, and commercializing innovative therapeutics for cancer and autoimmune diseases. The company operates primarily in the biotechnology sector and is dedicated to bringing novel therapies to patients in need. Zai Lab's core products include a range of drug candidates that target various oncology and autoimmune indications, leveraging its robust research and development capabilities.
ZLAB Company Deck
ZLAB Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presents a generally positive outlook for Zai Lab, with strong revenue growth and a clear path towards profitability. VYVGART shows significant promise in the Chinese market, supported by updated guidelines. However, there are challenges such as competitive pressures on ZEJULA and supply issues affecting XACDURO. The company's diversified pipeline and strategic use of AI and local expertise provide a solid foundation for future growth.View all ZLAB earnings summariesZLAB Stock 12 Month Forecast
Average Price Target
$55.63
▲(111.20% Upside)
Technical Analysis
Ownership Overview
1.73% Insiders
13.03% Mutual Funds
0.30% Other Institutional Investors
84.14% Public Companies and
Individual Investors